Farallon Capital Management LLC Ionis Pharmaceuticals Inc Transaction History

Farallon Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$36.45 - $47.7 $26.6 Million - $34.8 Million	-729,200 Reduced 99.35%	4,800 $228,000
Q1 2024 May 15, 2024	SELL	$42.03 - $53.55 $34.5 Million - $44 Million	-821,020 Reduced 52.8%	734,000 $31.8 Million
Q4 2023 Feb 14, 2024	BUY	$43.39 - $51.63 $67.5 Million - $80.3 Million	1,555,020 New	1,555,020 $78.7 Million
Q3 2023 Nov 14, 2023	BUY	$38.5 - $47.13 $28 Million - $34.3 Million	727,000 New	727,000 $33 Million
Q2 2023 Aug 14, 2023	BUY	$34.73 - $43.33 $173,649 - $216,650	5,000 New	5,000 $205,000
Q1 2021 May 17, 2021	SELL	$42.51 - $63.78 $5.08 Million - $7.62 Million	-119,500 Reduced 15.93%	630,500 $28.3 Million
Q4 2020 Feb 16, 2021	BUY	$45.3 - $60.27 $34 Million - $45.2 Million	750,000 New	750,000 $42.4 Million
Q1 2018 May 15, 2018	SELL	$44.08 - $55.05 $28.4 Million - $35.5 Million	-645,000 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$50.3 - $64.39 $9.81 Million - $12.6 Million	195,000 Added 43.33%	645,000 $32.4 Million
Q3 2017 Nov 14, 2017	BUY	$45.56 - $59.57 $20.5 Million - $26.8 Million	450,000	450,000 $22.8 Million

407

136M

862K

582K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $4.53B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Farallon Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Farallon Capital Management LLC with notifications on news.